Drugs / BLI800
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00583713 | Aug 2007 → Apr 2008 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02189850 | Jun 2014 → Jan 2015 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 36 trials · 1 met primary | ||||||
| Phase 3 | NCT03562884 | Jul 2018 → Apr 2019 | — | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT02819323 | Jun 2016 → Mar 2018 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01501513 | Dec 2011 → Mar 2013 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00856843 | Feb → May 2009 | — | Braintree Laboratories | Completed | Met primary |
| Phase 3 | NCT00503607 | Jul → Nov 2007 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00503815 | Jul → Nov 2007 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04214301 | Sep → Nov 2019 | — | Braintree Laboratories | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLI-800 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00503815 ↗ |
| Route | Oral | “BLI-800 oral solution” NCT00583713 ↗ |